

2026

•G Adornetto, G Caglio, K Whitehouse, S Dolati , A Dax , R-S Wedemeyer, A Warnke, **T Rautenberg**, E Rapti. Effectiveness of a salivary progesterone-based fertility awareness contraceptive method. *Contraception* 2026; 157

2025

•**IJM Duijkers, C Klipping, C Draeger**, BS Schug, R-S Wedemeyer, Y Li, JC Arjona Ferreira, EM Migoya. Inhibition of ovulation and pharmacologic mechanism of action of relugolix combination therapy. *Fertil Steril*, 2025 Aug;124(2):344-354

2022

•**IJM Duijkers, C Klipping, T Rautenberg**, BS.Schug, PS.Kochhar, H Osterwald, M Oettel.Effect on ovarian activity and ovulation inhibition of different oral dosages of levonorgestrel.*Contraception* 2022;110:6-15

2021

•K Erb-Zohar, H Sourgens, K Breithaupt-Groegler, **C Klipping**. Unintended drug exposure during pregnancy in clinical trials – a survey in early drug development. *International Journal of Clinical Pharmacology and Therapeutics* 2021;59:26-30

2021

•**I Duijkers, C Klipping**, V Kinet, M Jost, A Bastidas, J-M Foidart. Effects of an oral contraceptive containing estetrol and drospirenone on ovarian function. *Contraception*2021;103:386-393

2021

•M-H Schultze-Mosgau, B Schütt, **C Draeger**, M Casjens, S Löwen, T Zimmermann, B Rohde.The effects of Vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive. *Br J Clin Pharmacol* 2021;87:925-936

2021

•**C Klipping, I Duijkers**, M Mawet, C Maillard, A Bastidas, M Jost, J-M Foidart. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone.*Contraception* 2021:103:213-221

2020

•J Douxfils, **C Klipping, I Duijkers**, M Jost, J Rosing, J-M Foidart. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.*Contraception* 2020,102:396-402.

2020

•**I.J.M. Duijkers, C. Klipping, C. Draeger**, B.S. Schug, A. Dax, M. Friedrich, K. Nickisch.Ovulation inhibition with a new vaginal ring containing trimegestone. *Contraception*2020;102:237-242.

2020

•C Banh, **T Rautenberg, I Duijkers**, P Borenzstein, C Monteil, D Levy-Gompel, **C Klipping**, BScherrer, A Glasier. The effects on ovarian activity of delaying versus immediately restarting combined oral contraception after missing three pills and taking ulipristal acetate 30 mg.*Contraception* 2020;102:145-151

2019

•MC Fox, **C Klipping**, AM Nguyen, TL Frenkl, SM Cruz, Y Wang, T Korver. A phase 2b multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of vaginal rings containing nomegestrol acetate or etonogestrel and 17 β -estradiol in the treatment of women with primary dysmenorrhea, *Contraception* 2019;99:125-130

2018

•**IJM Duijkers**, I Klingmann, R Prinz, M Wargenau, S Hrafnisdottir, Th B Magnúsdóttir, **C Klipping**. Effect on endometrial histology and pharmacokinetics of different dose regimens of progesterone vaginal pessaries, in comparison with progesterone vaginal gel and placebo. *Human Reproduction* 2018;33:2131-2140

2018

•B. Schütt, M-H. Schultze-Mosgau, **C. Draeger**, Xinying Chang, S. Löwen, A. Kaiser, B. Rohde: Effect of the Novel Selective Progesterone Receptor Modulator Vilaprisan on Ovarian Activity in Healthy Women. *J Clin Pharmacol.* 2018 Feb;58(2):228-239

2018

•**I Duijkers**, **C Klipping**, **D Heger-Mahn**, GN Fayad, TL Frenkl, SM Cruz, T Korver. Phase II dose-finding study on ovulation inhibition and cycle control associated with the use of contraceptive vaginal rings containing 17 β estradiol and the progestagens etonogestrel or nomegestrol acetate compared to NuvaRing. *Eur J Contracept Reprod Biol* 2018;23:245-254

2017

•K Abd-Elaziz, **I Duijkers**, L Stöckl, B Dietrich, **C Klipping**, K Eckert, S Goletz. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator controlled pharmacokinetic and pharmacodynamic trials. *Hum Reprod* 2017;32:1639-1647.

2017

•C Kluft, Y Zimmerman, M Mawet, **C Klipping**, **IJM Duijkers**, J Neuteboom, J-M Foidart, H Coelingh Bennink. Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol. *Contraception* 2017;95:140-7.

2016

•MGF Gerrits, H Kramer, R el Galta, G van Beerendonk, R Hanssen, K Abd-Elaziz, **C Klipping**, **I Duijkers**, SA Stoch. Oral follicle-stimulating hormone agonist tested in healthy young women of reproductive age failed to demonstrate effect on follicular development but affected thyroid function. *Fertil Steril* 2016;105:1056-1062.

2016

•M.-H. Schultze-Mosgau, K.Waellnitz, R. Nave, S. Klein, J. Kraetzschmar, **T. Rautenberg**, H. Schmitz & B. Rohde. Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial, *Hum Reprod.* 2016 Aug;31(8):1713-22

2016

•**IJM Duijkers**, **D Heger-Mahn**, D Drouin, S Skouby. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. *Contraception* 2016;93:303-309.

2016

•K Waellnitz, **I Duijkers**, **C Klipping**, **T Rautenberg**, B Rohde, C Zurth. A two-centre, open-label, randomised study of ovulation inhibition with three transdermal contraceptive patches, each containing different amounts of ethinyl oestradiol and gestodene in healthy, young women. *J Obstet Gynaecol* 2016 Jan;36(1):106-13.

2015

•V Brache, L Cochon, **IJM Duijkers**, DP Levy, N Kapp, C Monteil, JL Abitbol, **C Klipping**. A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception. Hum Reprod 2015 Dec;30(12):2785-93.

2015

•**IJ M Duijkers, D Heger-Mahn**, D Drouin, S Skouby. A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen. Eur J Contr Reprod Health Care 2015; 20: 419-427.

2015

•**I.J.M. Duijkers, C. Klipping**, Y. Zimmerman, N. Appels, M. Jost, C. Maillard, M. Mawet, J-M. Foidart, H.J.T. Coelingh Bennink. Inhibition of ovulation by administration of estetrol in combination with Drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study. Eur J Contr Reprod Health Care 2015; 20; 476-489.

2015

•M Mawet, C Maillard, **C Klipping**, Y Zimmerman, J-M Foidart, HJT Coelingh Bennink. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. Eur J Contrac Reprod Health Care, 2015; online: 1–13

2015

•ST Cameron, C Berger, L Michie, **C Klipping**, K Gemzell-Danielsson. The effects on ovarian activity of ulipristal acetate when 'quickstarting' a combined oral contraceptive pill: a prospective, randomized, double-blind parallel-arm, placebo-controlled study. Hum Reprod 2015;30:1566-72.

2014

•**D Heger-Mahn**, G Pabst, A Dienel, S Schläfke, **C Klipping**. No interacting influence of Lavender oil preparation Silexan on oral contraception using an ethinylestradiol /levonorgestrel combination. Drugs RD 2014;14:265-72

2013

•KD Cobey, AP Buunk, TV Pollet, **C Klipping**, S Craig Roberts. Men perceive their female partners and themselves, as more attractive around ovulation. Biol Psychol, 2013;94:513- 516

2013

•J Endrikat, S Parke, D Trummer, M Serrani, **I Duijkers, C Klipping**. Pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive: results of a randomized, open-label study. Contraception, 2013;87(2):227-34.

2013

•W. Junge, **D. Heger-Mahn**, Dietmar Trummer, Martin Merz. Investigation of the hemostatic effect of a transdermal patch containing 0,55 mg ethinyl estradiol and 2,1 mg gestodene compared with a monophasic oral contraceptive containing 0,03 mg ethinyl estradiol and 0,15 mg levonorgestrel: an open-label, randomized, cross-over study. Drugs R D 2013;13:223-33

2012

•**Christine Klipping, Ingrid Duijkers**, Michel P Fortier, Joachim Marr, Dietmar Trummer, Jörg Elliesen. Contraceptive efficacy and tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomized, controlled study. J Fam Planning Reprod Health Care 38:73-83, 2012

2012

• **Christine Klipping, Ingrid Duijkers**, Michel P Fortier, Joachim Marr, Dietmar Trummer, Jörg Elliesen. Long-term tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: results from a randomized, controlled, multicentre study. *J Fam Planning Reprod Health Care* 38:84-93, 2012

2012

• Hartmut Blode, **Christine Klipping**, Frank Richard, Dietmar Trummer, Beate Rohde, Konstanze Diefenbach. Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone. *Contraception* 85:178184,2012

2012

• Yuzuru Anzai, **Doris Heger-Mahn**, Ilka Schellschmidt, Joachim Marr: Suppression of ovarian activity with a low-dose 21/7-day regimen oral contraceptive containing ethinylestradiol 20 mcg/drospirenone 3 mg in Japanese and Caucasian women, *Contraception* 2012;86:28-34

2012

• **Christine Klipping, Ingrid Duijkers, Ageeth Remmers**, Thomas Faustmann, Christian Zurth, Stefan Klein, Barbara Schütt. Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. *J Clin Pharmacol* 2012 52: 1704

2012

• Peter Schnabel, Gabriele S Merki-Feld, Alice Malvy, **Ingrid Duijkers**, Ellen Mommers, Michiel W. van den Heuvel. Bioequivalence and X-Ray Visibility of a Radiopaque Etonogestrel Implant versus a Non-Radiopaque Implant: A 3-Year, Randomized, Double-Blind Study. *Clinical Drug Investigation*, 2012;32:413-422.

2011

• **Christine Klipping, Ingrid Duijkers**, Susanne Parke, Uwe Mellinger, Marco Serrani, Wolfgang Junge. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. *Drugs RD* 11:159-170, 2011

2011

• Leena Anttila, Gloria Bachmann, László Hernádi, Michael Kunz, Joachim Marr, **Christine Klipping**. Contraceptive efficacy of a combined oral contraceptive containing ethinylestradiol 20 µg/drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis of four open-label studies. *Eur J Obstet Gynecol Reprod Biol* 155:180-182, 2011

2010

• **Ingrid JM Duijkers, Christine Klipping**, Paul Grob, Tjeerd Korver. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol. *European Journal of Contraception and Reproductive Health Care*, 2010 Oct;15(5):314-25

2010

• **Ingrid JM Duijkers, Christine Klipping**. Polycystic ovaries, as defined by the 2003 Rotterdam consensus criteria, are found to be very common in young healthy women. *Gynaecological Endocrinology*, 2010 Mar;26(3):152-60

2008

• **Klipping C, Duijkers I**, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. *Contraception* 78: 16-25, 2008

2008

• Endrikat J, Parke S, Trummer D, Schmidt W, **Duijkers I, Klipping C**. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. *Contraception*, 2008 Sep;78(3):218-25

2008

• Hemelaar M, Kenemans P, Hack CE, **Klipping C**, van der Mooren MJ. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial. *Menopause* 15: 248-255, 2008

2008

• E Mommers, WM Kersemaekers, J Elliesen, M Kepers, D Apter, HM Behre, J Beynon, PM Bouloux, A Costantino, H-P Gerbershagen, L Grønlund, **D Heger-Mahn**, I Huhtaniemi, EL Koldewijn, **C Lange**, S Lindenberg, MC Meriggiola, E Meuleman, PFA Mulders, E Nieschlag, A Perheentupa, A Solomon, L Väisälä, FC Wu, M Zitzmann. Male hormonal contraception: a double-blind, placebo-controlled study *J Clin Endocrinol Metab* 2008;93:2572-80.

2005

• R Massai, L Mäkäräinen, A Kuukankorpi, **C Klipping, I Duijkers**, T Dieben. The combined contraceptive vaginal ring and bone mineral density in healthy pre-menopausal women. *Human Reproduction* 20:2764-2768, 2005

2005

• **Christine Klipping**, Joachim Marr. Effects of two combined oral contraceptives containing ethinyl estradiol 20 µg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. *Contraception* 71: 409-416, 2005

2005

• **Ingrid JM Duijkers**, Lonneke Engels, **Christine Klipping**. Length of the menstrual cycle after discontinuation of oral contraceptives. *Gynecological Endocrinology* 20: 74-79, 2005

2005

• Tjeerd Korver, **Christine Klipping, Doris Heger-Mahn, Ingrid Duijkers**, Gonnie van Osta, Thom Dieben. Maintenance of ovulation inhibition with the 75-µg desogestrel-only contraceptive pill (Cerazette®) after scheduled 12-h delays in tablet intake. *Contraception*, 71:8-13, 2005

2004

• **D Heger-Mahn**, C Warlimont, T Faustmann, C Gerking, **C Klipping**. Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers. *European Journal of Contraception and Reproductive Health Care*, 9:173-181, 2004

2004

• **Ingrid JM Duijkers, Christine Klipping**, Carole HJ Verhoeven, Thom OM Dieben. Ovarian function with the contraceptive vaginal ring (NuvaRing) or an oral contraceptive: a randomized study. *Human Reproduction*, 19: 2668-2673, 2004

2004

• **Ingrid JM Duijkers**, Carole HJ Verhoeven, Thom OM Dieben, **Christine Klipping**. Follicular growth during pill or ring treatment depends on the day of ovulation in the pre-treatment cycle. *Human Reproduction*, 19: 2674-2679, 2004

2004

• **D Heger-Mahn**, C Warlimont, T Faustmann, C Gerlinger, **C Klipping**. Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers. *The European Journal of Contraception and Reproductive Health Care*, 9: 173-181, 2004

2004

• **Ingrid JM Duijkers**, Leoni A Louwé, Ddid DM Braat, **Christine Klipping**. One, two or three: how many directions are useful in transvaginal ultrasound measurement of ovarian follicles? *European Journal of Obstetrics and Gynecology*, 117: 60-63, 2004

2004

• **I Duijkers**, S Killick, A Bigrigg, T Dieben. A comparative study on the effects of a contraceptive vaginal ring NuvaRing and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function. *European Journal of Reproductive Health Care*, 9: 131-140, 2004

2003

• Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. *Contraception* 2003;67:173-185

2003

• Nagaraja NV, Pechstein B, Erb K, **Klipping C**, Hermann R, Locher M, Derendorf H. Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women. *J Clin Pharmacol* 2003;43:243-251

2002

• **Ingrid J.M. Duijkers**, **Christine Klipping**, Peter J. Boerrigter, Christel S.M. Machielsen, Joris J. de Bie and Gerrit Voortman. Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. *Human Reproduction* 2002;8:1987-1993

2002

• J. Endrikat, **C. Klipping**, M. Cronin, C.Gerlinger, A. Ruebig, W. Schmidt, B. Dueterberg. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20mg ethinyl estradiol and 100mg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. *Contraception* 2002;65:215-221

2001

• J. Endrikat, **C. Klipping**, C.Gerlinger, A. Ruebig, W.Schmidt, T. Holler, B. Dueterberg. A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 mg ethinyl estradiol and 75 mg gestodene and a 21-day regimen with 30 mg ethinyl estradiol and 75 mg gestodene on hemostatic variables, lipids, and carbohydrate metabolism. *Contraception* 2001;64:235-241

2001

• Van Hoof HJ, de Sevaux RG, van Baelen H, Swinkels LM, **Klipping C**, Ross HA, Sweep CG. Relationship between free and total 1,25-dihydroxyvitamin D in condition of modified binding. *Eur J Endocrinol* 2001;144:391-396

2001

• Erb K, **Klipping C**, **Duijkers I**, Pechstein B, Schueler A, Hermann R. Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women. *Fertility and Sterility*, 75: 316-323, 2001

2000

• **Duijkers IJM, Klipping C.** Ultrasonographic assessment of endocervix and cervical mucus in ovulatory menstrual cycles. *Eur J Obstet Gynecol Reprod Biol*, 93: 13-17, 2000

2000

• Nagaraja NV, Pechstein B, Erb K, **Klipping C**, Hermann R, Niebch G, Derendorf H. Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. *Clin Pharmacol Ther* 2000;68:617-625

1999

• Oral Contraceptive and Hemostasis Study Group. An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables. *Contraception* 1999;59:345-355

1999

• Van der Mooren MJ, **Klipping C**, van Aken B, Helmerhorst E, Spielmann D, Kluff C. A comparative study of the effects of gestodene 60 µg/ethinylestradiol 15 µg and desogestrel 150 µg/ ethinylestradiol 20 µg on hemostatic balance, blood lipid levels and carbohydrate metabolism. *Eur J Contracept Reprod Health Care* 1999;4 suppl 2:27-35

1998

• **Duijkers IJM, Klipping C**, Willemsen WNP, Krone D, Schneider E, Niebch G, Hermann R. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist cetrorelix in healthy female volunteers. *Human Reproduction* 1998;13: 2392-2398

1998

• **C. Klipping and D. Heger-Mahn.** Discussion on early clinical drug development in the target population with respect to the field of reproductive endocrinology. *Int J Clin Pharm* 1998;36:591-593

1997

• **IJM Duijkers, C Klipping**, TMT Mulders, HJ Out, HJT Coelingh Bennink, HM Vemer. Pharmacodynamics and pharmacokinetics after repeated subcutaneous administration of three gonadotrophin preparations. *Human Reproduction* 1997;12: 2379-2384

1997

• K Breithaupt-Grögler, **D Heger-Mahn, C Klipping**, R Butzer, **I Duijkers**, D Geyer, R Hermann, C Hinze, M Mahler, M Seibert-Grafe, K Westermann. Klinische Arzneimittelprüfung an Frauen. Überlegungen zum Thema Schwangerschaftsverhütung. *Deutsches Ärzteblatt* 1997;94: A-991-993

1997

• Hermann R, **Heger-Mahn D**, Mahler M, Seibert-Grafe M, **Klipping C**, Breithaupt Grögler K, de Mey C. Adverse events and discomfort in studies on healthy subjects: the volunteer's perspective. *Eur J Clin Pharmacol* 1997;53:207-214